{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:17:13Z","timestamp":1795133833366,"version":"4.10.3"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Recently, a formula of subcutaneous infliximab (SC-IFX) has been approved for inflammatory bowel disease (IBD), demonstrating a better pharmacokinetic and immunogenic profiles, compared to intravenous infliximab (IV-IFX), with similar efficacy and safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Aim<\/jats:title>\n            <jats:p>The aim of this study is to evaluate the clinical, biochemical, and pharmacological outcomes of IBD patients in clinical remission, who switched from IV-IFX to SC-IFX, with a follow-up period of 6\u2005months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Retrospective cohort study, including IBD patients in clinical remission, previously medicated with IV-IFX, who switched to SC-IFX 120\u2005mg every other week. Biochemical parameters were evaluated before the switch and 6\u2005months after, namely infliximab serum concentrations, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and fecal calprotectin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Included 41 patients in clinical remission, 32 with Crohn\u2019s disease (78.0%) and 9 with ulcerative colitis (22.0%). All patients maintained clinical remission during the 6\u2005months after the switch, with a treatment persistence rate of 100%, and no patients requiring corticosteroid therapy, switching back to IV-IFX, or IBD-related hospitalization. The mean infliximab serum concentrations were significantly higher after 6\u2005months of SC-IFX (17.3\u2005\u00b1\u20056.6 vs. 9.1\u2005\u00b1\u20055.5\u2005\u00b5g\/ml, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u20050.001). However, there were no differences between values of ESR, CRP, and fecal calprotectin, before and after the switch (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.791, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.246, and <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u20050.639). Additionally, none of the patients developed antibodies to infliximab.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Switching from IV-IFX to SC-IFX in IBD patients in clinical remission is effective and leads to higher infliximab serum concentrations, regardless of the combination with immunomodulatory therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/meg.0000000000002835","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T01:19:32Z","timestamp":1724289572000},"page":"1314-1318","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Subcutaneous versus intravenous infliximab therapy \u2013 a real-world study: toward higher drug concentrations"],"prefix":"10.1097","volume":"36","author":[{"given":"Ana Isabel","family":"Ferreira","sequence":"first","affiliation":[{"name":"Gastroenterology Department, Hospital Senhora da Oliveira \u2013 Guimar\u00e3es, Guimar\u00e3es"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga"},{"name":"ICVS\/3B\u2019s, PT Government Associate Laboratory, Guimar\u00e3es, Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago","family":"Lima Capela","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Senhora da Oliveira \u2013 Guimar\u00e3es, Guimar\u00e3es"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga"},{"name":"ICVS\/3B\u2019s, PT Government Associate Laboratory, Guimar\u00e3es, Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e1tia","family":"Arieira","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Senhora da Oliveira \u2013 Guimar\u00e3es, Guimar\u00e3es"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga"},{"name":"ICVS\/3B\u2019s, PT Government Associate Laboratory, Guimar\u00e3es, Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Xavier","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Senhora da Oliveira \u2013 Guimar\u00e3es, Guimar\u00e3es"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga"},{"name":"ICVS\/3B\u2019s, PT Government Associate Laboratory, Guimar\u00e3es, Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Cotter","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Hospital Senhora da Oliveira \u2013 Guimar\u00e3es, Guimar\u00e3es"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga"},{"name":"ICVS\/3B\u2019s, PT Government Associate Laboratory, Guimar\u00e3es, Braga, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial.","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"R2-20250812","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis.","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"R3-20250812","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(21)00377-0","article-title":"Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.","volume":"7","author":"Lasa","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","article-title":"Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease.","volume":"160","author":"Schreiber","year":"2021","journal-title":"Gastroenterology"},{"key":"R5-20250812","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1093\/ecco-jcc\/jjac053","article-title":"Efficacy and safety of elective switching from intravenous to subcutaneous infliximab [CT-P13]: a multicentre cohort study.","volume":"16","author":"Smith","year":"2022","journal-title":"J Crohns Colitis"},{"key":"R6-20250812","first-page":"118","article-title":"Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results.","volume":"114","author":"Arg\u00fcelles-Arias","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"R7-20250812","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/ibd\/izad094","article-title":"One-year clinical outcomes of subcutaneous infliximab maintenance therapy compared with intravenous infliximab maintenance therapy in patients with inflammatory bowel disease: a prospective cohort study.","volume":"30","author":"Hong","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/j.cgh.2022.08.011","article-title":"Effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases: the REMSWITCH study.","volume":"21","author":"Buisson","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/apt.17822","article-title":"Long-term effectiveness and acceptability of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel disease treated with intensified doses: the REMSWITCH-LT study.","volume":"59","author":"Buisson","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-20250812","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/ibd\/izac119","article-title":"Comparative acceptability of therapeutic maintenance regimens in patients with inflammatory bowel disease: results from the nationwide ACCEPT2 study.","volume":"29","author":"Buisson","year":"2023","journal-title":"Inflamm Bowel Dis"},{"key":"R11-20250812","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s12325-021-01990-6","article-title":"Perspectives on subcutaneous infliximab for rheumatic diseases and inflammatory bowel disease: before, during, and after the COVID-19 era.","volume":"39","author":"Schreiber","year":"2022","journal-title":"Adv Ther"},{"key":"R12-20250812","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/00365521.2023.2285229","article-title":"Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses.","volume":"59","author":"Harno-Tasihin","year":"2023","journal-title":"Scand J Gastroenterol"},{"key":"R13-20250812","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3390\/biomedicines10092130","article-title":"Subcutaneous infliximab [CT-P13], a true biologic 2.0. real clinical practice multicentre study.","volume":"10","author":"Huguet","year":"2022","journal-title":"Biomedicines"},{"key":"R14-20250812","first-page":"549","article-title":"Safety and efficacy of transitioning inflammatory bowel disease patients from intravenous to subcutaneous infliximab: a single-center real-world experience.","volume":"36","author":"Jeffrey","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"R15-20250812","doi-asserted-by":"crossref","first-page":"7296","DOI":"10.3390\/jcm11247296","article-title":"Inflammatory bowel disease patients\u2019 acceptance for switching from intravenous infliximab or vedolizumab to subcutaneous formulation: the Nancy experience.","volume":"11","author":"Remy","year":"2022","journal-title":"J Clin Med"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S2468-1253(20)30392-7","article-title":"From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.","volume":"6","author":"Verma","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R17-20250812","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ecco-jcc\/jjad188","article-title":"Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease.","volume":"18","author":"Roblin","year":"2023","journal-title":"J Crohns Colitis"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases.","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"R19-20250812","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40261-023-01252-z","article-title":"Subcutaneous infliximab monotherapy versus combination therapy with immunosuppressants in inflammatory bowel disease: a post hoc analysis of a randomised clinical trial.","volume":"43","author":"D\u2019Haens","year":"2023","journal-title":"Clin Drug Investig"}],"container-title":["European Journal of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:01:01Z","timestamp":1755014461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000002835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000002835","relation":{},"ISSN":["0954-691X","1473-5687"],"issn-type":[{"value":"0954-691X","type":"print"},{"value":"1473-5687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}